4//SEC Filing
ACURA PHARMACEUTICALS, INC 4
Accession 0001209191-15-054770
$ACURCIK 0000786947operating
Filed
Jun 17, 8:00 PM ET
Accepted
Jun 18, 6:09 PM ET
Size
15.4 KB
Accession
0001209191-15-054770
Insider Transaction Report
Form 4
GALEN PARTNERS III L P
10% Owner
Transactions
- Sale
Common Stock
2015-06-16$1.08/sh−100,923$109,441→ 10,982,574 total(indirect: See FN) - Sale
Common Stock
2015-06-17$1.05/sh−3,900$4,095→ 10,978,674 total(indirect: See FN)
CLAUDIUS LLC
10% Owner
Transactions
- Sale
Common Stock
2015-06-16$1.08/sh−100,923$109,441→ 10,982,574 total(indirect: See FN) - Sale
Common Stock
2015-06-17$1.05/sh−3,900$4,095→ 10,978,674 total(indirect: See FN)
GALEN PARTNERS INTERNATIONAL III L P
10% Owner
Transactions
- Sale
Common Stock
2015-06-16$1.08/sh−100,923$109,441→ 10,982,574 total(indirect: See FN) - Sale
Common Stock
2015-06-17$1.05/sh−3,900$4,095→ 10,978,674 total(indirect: See FN)
GALEN EMPLOYEE FUND III LP
10% Owner
Transactions
- Sale
Common Stock
2015-06-16$1.08/sh−100,923$109,441→ 10,982,574 total(indirect: See FN) - Sale
Common Stock
2015-06-17$1.05/sh−3,900$4,095→ 10,978,674 total(indirect: See FN)
Galen Management, LLC
10% Owner
Transactions
- Sale
Common Stock
2015-06-17$1.05/sh−3,900$4,095→ 10,978,674 total(indirect: See FN) - Sale
Common Stock
2015-06-16$1.08/sh−100,923$109,441→ 10,982,574 total(indirect: See FN)
Footnotes (5)
- [F1]The shares were sold as follows: 92,199 by Galen Partners III, L.P. ("Galen III"), 8,345 by Galen Partners International III, L.P. ("Galen International") and 379 by Galen Employee Fund III, L.P. ("Employee Fund").
- [F2]The shares were sold at prices between $1.05 and $1.14. The Reporting Entities will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]The shares are held as follows: 10,036,254 by Galen III, 904,976 by Galen International and 41,344 by Employee Fund. Claudius, L.L.C. serves as the sole General Partner of Galen III and Galen International and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Galen Management, L.L.C. serves as the sole General Partner of Employee Fund and has sole voting and investment control over the shares held by Employee Fund and may be deemed to beneficially own the shares held by Employee Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein, except to the extent of its respective pecuniary interest therein.
- [F4]The shares were sold as follows: 3,563 by Galen III, 322 by Galen International and 15 by Employee Fund.
- [F5]The shares are held as follows: 10,032,691 by Galen III, 904,654 by Galen International and 41,329 by Employee Fund. Claudius, L.L.C. serves as the sole General Partner of Galen III and Galen International and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Galen Management, L.L.C. serves as the sole General Partner of Employee Fund and has sole voting and investment control over the shares held by Employee Fund and may be deemed to beneficially own the shares held by Employee Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein, except to the extent of its respective pecuniary interest therein.
Documents
Issuer
ACURA PHARMACEUTICALS, INC
CIK 0000786947
Entity typeoperating
IncorporatedNY
Related Parties
1- filerCIK 0000786947
Filing Metadata
- Form type
- 4
- Filed
- Jun 17, 8:00 PM ET
- Accepted
- Jun 18, 6:09 PM ET
- Size
- 15.4 KB